Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

TEER of the Calu-3 cell monolayers measured at a 12-h interval. by Aizat Turdalieva (2512252)

Transepithelial electrical resistance (TEER) (N = 6). by Shirko Marcel Shokr (19173337)

Affinity analysis results (with a confidence level above 50%). by Marta R. Jabłońska (8491404)

Log reactivation results for exposures by 222 nm or 265 nm with or without UV-A 365 nm pre-treatment. by Daniel Ma (12698752)

Inhibition of 40 nm NP uptake by CPZ leads to decreased concentration of NPs in the MLNs. by Savannah E. Howe (514695)

The 599 peptide-mediated silencing of CIP2A decreases oral cancer cell invasiveness and anchorage-independent growth. by Liliana Cantini (453377)

24-hr treatment with 100nM M64HCl, 10μM PF573228, the combination of 100nM M64HCl and 10μM PF573228, 10μM PD98059, or the combination of 100nM M64HCl and 10μM PD98059 in migrating... by Sema Oncel (10152053)

Subjects:

24-hr treatment with 100nM M64HCl, 10μM PF573228, the combination of 100nM M64HCl and 10μM PF573228, 10μM PD98059, or the combination of 100nM M64HCl and 10μM PD98059 in migrating... by Sema Oncel (10152053)

Subjects:

Fluorescent intensity at 520 nm (RNase A/B) and 556 nm (DNase I) versus time for nucleases in DI water lysed with Lyse-It at 30% and 50% power for varying time. by Tonya M. Santaus (5559077)

“…<b>(A)</b> 20 pM RNase A <b>(B)</b> 46 pM RNase B, <b>(C)</b> 10.5 nM DNase I. As microwave power and time increase, nuclease activity decreases.…”

Dose- and time-dependent effect of IL-1β treatment on HBMEC barrier function using TEER. by Janet Storm (37473)

The distributions of the end-simulation adolescence-limited proportion when (a) <i>k</i> is increased or decreased by 50%, (b) <i>c</i> is increased or decreased by 50%, (c) <i>γ</i> is increased or decreased by 50%, and (d) Δ<i>e</i> is increased or decreased by 50%, compared against the benchmark distribution <i>F</i>(<b>p</b>₀) for the parameters shown in Table 1. by Jia Ning Leaw (752775)

The decrease in hBMVEC death is associated with reduced activation of Caspase-3. by Simona F. Spampinato (773594)

siRNA-mediated knockdown of SPARC decreases SLUG expression in a p53-independent manner. by Nina Fenouille (149658)

Numerical simulation of the time evolution of the interaction between three human plasma proteins and 50∶50 NIPAM/BAM NP with 70 nm diameter. by Daniele Dell'Orco (76455)

Myoferlin knockdown decreases the expression of tight junction molecule ZO-1. by Cleo Leung (152795)

Effects of ROCK inhibitors H-1152 and Y-27632 on TNF-induced MLC phosphorylation, actin and CL5 reorganization and the fall in TEER. by Paul R. Clark (714064)

“…D) Effects of H-1152 and Y-27632 on the phase 1 and phase 2 TEER decreases induced by TNF. Starting at T₀, HDMEC plated on ECIS 96-well arrays received a 1 hour pre-treatment with vehicle (top panel, n = 4, 4) or with a ROCK inhibitor, either H-1152 (at 1 or 10 μM, middle panel, n = 6, 6) or Y-27632 (at 1 or 10 μM, bottom panel, n = 6, 6). …”